Why is telolipidol more powerful than other weight loss drugs? ——The scientific principle of GLP-1/GIP dual stimulation
At present, there are more and more choices for weight loss drugs, from traditional appetite suppressants and fat absorption inhibitors to today's GLP-1 drugs . Scientific development has provided new possibilities for weight management. Among them, telpotide, as the first GLP-1/GIP dual agonist, is considered to be the strongest weight loss drug at present , and its clinical research results far exceed other similar drugs.
So, what is the strength of tilpotide? How do the two hormones, GLP-1 and GIP, work together to make weight loss more efficient? This article will deeply analyze the mechanism of action of tilpotide, the comparison with other weight loss drugs, and why it is superior in metabolic regulation .
1. Limitations of traditional weight loss drugs: Why do many people fail to lose weight?
📌 Current mainstream weight loss drugs include:
- GLP-1 monoagonists (such as semaglutide, liraglutide): reduce appetite and delay gastric emptying , but do not directly affect fat metabolism.
- Fat absorption inhibitors (such as orlistat): Inhibit fat absorption but have limited effects on appetite and metabolism.
- Appetite suppressants (such as amphetamines, naltrexone - bupropion): affect brain neurotransmitters , are effective in the short term, but have a risk of addiction.
Although these drugs can help with weight loss to a certain extent, many people regain weight after stopping the medication, or the side effects are significant, making it difficult to use them long-term . In particular, GLP-1 monoagonists, although effective, have limited effects on fat metabolism , resulting in unsatisfactory weight loss results for some people.
💡 Conclusion: Weight loss drugs with a single mechanism have bottlenecks and cannot meet the needs of everyone.
2. Dual agonist mechanism of tepote: How do GLP-1 + GIP work synergistically?
📌 GLP-1 (glucagon-like peptide -1 ): reduces appetite and controls blood sugar
• It acts on the hypothalamic appetite center of the brain, reducing hunger and lowering daily calorie intake.
• Delays gastric emptying , allowing food to stay in the stomach longer and increasing the feeling of fullness.
• Promote insulin secretion, lower blood sugar, and reduce glucagon release.
📌 GIP (glucose-dependent insulinotropic polypeptide): promotes fat decomposition and improves metabolism
• It acts on fat cells, improves fat oxidation capacity , and promotes body fat consumption, rather than just reducing appetite.
• Enhance insulin sensitivity , reduce insulin resistance, and help people with prediabetes and metabolic syndrome improve their metabolic health more quickly.
• Reduce the common gastrointestinal side effects of GLP-1 drugs (such as nausea and vomiting).
Core differences:
• Traditional GLP-1 agonists mainly reduce appetite but do not directly affect fat metabolism.
• GIP additionally promotes fat decomposition and increases the body's energy expenditure , making the weight loss effect of tebuconazole far superior to other GLP-1 drugs.
💡 Conclusion: GLP-1 mainly acts on " reducing intake " , while GIP can also " accelerate consumption " , making tipolamine more effective in weight loss.
3. Telbutide vs. other weight loss drugs: clinical data comparison
|
Research |
Telportide ( GLP-1/GIP ) |
Semaglutide ( GLP-1 monoagonist) |
Orlistat (fat absorption inhibitor) |
|
Weight loss ratio |
22.5% weight loss after 72 weeks ( SURMOUNT-1 study) |
16.9% weight loss after 68 weeks ( STEP-1 study) |
7-10% weight loss after 1 year ( XENICAL study) |
|
Proportion of patients with weight loss ≥ 20% |
57% |
36% |
Less than 10% |
|
Main mechanism of action |
Reduce appetite + promote fat metabolism + enhance insulin sensitivity |
Reduce appetite + delay gastric emptying |
Reduces fat absorption without affecting appetite |
📌 Data Analysis:
• The weight loss rate of tebuconazole was as high as 22.5% , which was 5.6% higher than that of semaglutide and nearly three times higher than that of orlistat.
• More than 57% of users lost more than 20% of their body weight , compared with only 36% for semaglutide.
• The GIP effect makes tipolamine superior in promoting fat burning and optimizing metabolism . It not only reduces calorie intake, but also " accelerates burning " .
💡 Conclusion: Clinical data have shown that the weight loss effect of tipol is significantly better than other GLP-1 drugs and traditional weight loss drugs.
4. Side effects and tolerability: Is telopoietin easier to use?
|
Side effect category |
Telportide ( GLP-1/GIP ) |
Semaglutide ( GLP-1 ) |
Orlistat (fat absorption inhibitor) |
|
Nausea and vomiting |
Mild ( 31% nausea, 18% vomiting) |
Severe ( 44% nausea, 24% vomiting) |
none |
|
Gastrointestinal discomfort (diarrhea, constipation) |
Lighter |
May be more serious |
Diarrhea, oily stools |
|
Long-term tolerance |
Higher, good adaptability to side effects |
Some patients stopped taking the drug due to nausea |
Some patients discontinued the drug due to gastrointestinal discomfort |
📌 in conclusion :
• The GIP effect of tipol can reduce GLP-1- related nausea and vomiting , making it better tolerated and easier for users to adhere to the regimen.
• In contrast, semaglutide has a higher incidence of nausea and vomiting, which some patients may find difficult to tolerate .
• Orlistat mainly affects gastrointestinal function (diarrhea, oily stools), but its weight loss effect is far inferior to that of GLP-1 drugs .
💡 Final conclusion: Tilpotide is not only more effective, but also better tolerated and more suitable for long-term use.
🛒Mounjaro 2.5mg *2 sticks / box*2
--------------------------------
Welcome to add customer service to get new customer discount
Customer Service 1 ： AobMedical
Customer Service 2 ： Aob202404
Kent : +1 6462071346
Asakusa makeup: +81 8070566715 
